SCHEMBL25739619

SCHEMBL25739619

Cc1cc(C)c(NC2CCN(C(=O)OC(C)(C)C)C2)c(Br)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 6/20 0.48
ALDH1A1 P00352 2/20 0.44
EHMT2 Q96KQ7 1/20 0.43
BRD4 O60885 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PIK3CD O00329 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
BTK Q06187 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
EPHX2 P34913 1/20 0.42
PARP1 P09874 1/20 0.42
FPR3 P25089 1/20 0.42
FPR2 P25090 1/20 0.42
IDH1 O75874 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25288540 1.00 USP30 (0.48) USP30ALDH1A1EHMT2BRD4NPC1
SCHEMBL25286817 0.88 IDH1 (0.49) USP30ALDH1A1EHMT2BRD4NPC1
SCHEMBL25291355 0.84 CCNK (0.39) ALDH1A1EHMT2MAPTPIK3CD
SCHEMBL25238790 0.81 EHMT2 (0.48) USP30ALDH1A1EHMT2BRD4NPC1
SCHEMBL31350500 0.78 HSD11B1 (0.43) USP30ALDH1A1BRD4NPC1MAPT
SCHEMBL31350523 0.77 BTK (0.44) USP30ALDH1A1BRD4NPC1MAPT
SCHEMBL1844533 0.77 EPHX2 (0.58) ALDH1A1NPC1MAPTMAPK1HTT
SCHEMBL20281702 0.76 USP30 (0.51) USP30ALDH1A1NPC1MAPTMAPK1
SCHEMBL20281689 0.76 USP30 (0.51) USP30ALDH1A1NPC1MAPTMAPK1
SCHEMBL20281690 0.76 USP30 (0.51) USP30ALDH1A1NPC1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2025-09-02 US disclosed
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed
WO-2023119233-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF USP7, USP28, USP1 USP30 6/4885ALDH1A1 2210/4885EHMT2 1760/4885
US-12404279-B2 Deubiquitinase inhibitors and methods of use thereof USP7, USP28, USP1 USP30 6/4885ALDH1A1 2210/4885EHMT2 1760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.